Development of a simple genotyping method for the HLA-A*31:01-tagging SNP in Japanese.

AIM To construct a simple, low-cost typing method for the surrogate marker of HLA-A*31:01, a risk factor for carbamazepine (CBZ) related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). MATERIALS & METHODS DNAs from Japanese SJS/TEN patients were used for genotyping and developing the assay. RESULTS HLA-A*31:01 was confirmed to be significantly associated with definite/probable cases of CBZ-related SJS/TEN (p = 0.0040). Three single nucleotide polymorphisms, rs1150738, rs3869066 and rs259945, were in absolute linkage disequilibrium with HLA-A*31:01 in 210 Japanese SJS/TEN patients. Robust genotyping of rs3869066 in ZNRD1-AS1 was developed using polymerase chain reaction-restriction fragment length polymorphism assays. CONCLUSION Single nucleotide polymorphism genotyping is less time consuming and cheaper than conventional HLA typing, and would be useful for identifying Japanese patients at risk of CBZ-related SJS/TEN.

[1]  S. Tsai,et al.  Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. , 2014, JAMA.

[2]  Y. Cheung,et al.  Rapid detection of HLA‐A*31:01 allele in DNA and blood samples using loop‐mediated isothermal amplification , 2014, The British journal of dermatology.

[3]  T. Taketani,et al.  Simple and rapid detection of HLA-A*31:01 for prediction of carbamazepine-induced hypersensitivity using loop-mediated isothermal amplification method. , 2014, Journal of dermatological science.

[4]  U. Amstutz,et al.  Recommendations for HLA‐B*15:02 and HLA‐A*31:01 genetic testing to reduce the risk of carbamazepine‐induced hypersensitivity reactions , 2014, Epilepsia.

[5]  R. Hui,et al.  Genotype-phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: strength and clinical correlations. , 2014, Journal of dermatological science.

[6]  E. Génin,et al.  HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis , 2013, The Pharmacogenomics Journal.

[7]  T. Mushiroda,et al.  Specific HLA types are associated with antiepileptic drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese subjects. , 2013, Pharmacogenomics.

[8]  Yoshiro Saito,et al.  Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury , 2013, Journal of Human Genetics.

[9]  H. Kitajima,et al.  HLA and SNP haplotype mapping in the Japanese population , 2012, Genes and Immunity.

[10]  Yusuke Nakamura,et al.  New pharmacogenetic test for detecting an HLA-A*31: 01 allele using the InvaderPlus assay , 2012, Pharmacogenetics and genomics.

[11]  Sang-Heon Cho,et al.  Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans , 2011, Epilepsy Research.

[12]  D. Beltramo,et al.  Rapid HCP5 single-nucleotide polymorphism genotyping: a simple allele-specific PCR method for prediction of hypersensitivity reaction to Abacavir. , 2011, Clinica chimica acta; international journal of clinical chemistry.

[13]  J. Fernández-López,et al.  Association of the genetic marker for abacavir hypersensitivity HLA-B*5701 with HCP5 rs2395029 in Mexican Mestizos. , 2011, Pharmacogenomics.

[14]  Michael R. Johnson,et al.  HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. , 2011, The New England journal of medicine.

[15]  Chen-Yang Shen,et al.  Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. , 2011, The New England journal of medicine.

[16]  Yusuke Nakamura,et al.  Genome-wide association study identifies HLA-A ∗ 3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population , 2022 .

[17]  N. Lennon,et al.  Next-generation sequencing for HLA typing of class I loci , 2011, BMC Genomics.

[18]  C. Sotozono,et al.  HLA‐B*1511 is a risk factor for carbamazepine‐induced Stevens‐Johnson syndrome and toxic epidermal necrolysis in Japanese patients , 2010, Epilepsia.

[19]  V. Soriano,et al.  Use of the HCP5 single nucleotide polymorphism to predict hypersensitivity reactions to abacavir: correlation with HLA-B*5701. , 2010, The Journal of antimicrobial chemotherapy.

[20]  M. Muramatsu,et al.  Human leukocyte antigen genotypes in carbamazepine‐induced severe cutaneous adverse drug response in Japanese patients , 2008, The Journal of dermatology.

[21]  Jacques Fellay,et al.  The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir. , 2008, The Journal of infectious diseases.

[22]  S. Mallal,et al.  HLA-B*5701 screening for hypersensitivity to abacavir. , 2008, The New England journal of medicine.

[23]  Pardis C Sabeti,et al.  A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC , 2006, Nature Genetics.

[24]  J. Roujeau.  Clinical heterogeneity of drug hypersensitivity. , 2005, Toxicology.

[25]  I. Ishii,et al.  Development of a simple method for detection of the HLA-A*31:01 allele. , 2013, Drug metabolism and pharmacokinetics.

[26]  J. Nishikawa,et al.  Development of a rapid and inexpensive assay for detecting a surrogate genetic polymorphism of HLA-B*58:01: a partially predictive but useful biomarker for allopurinol-related Stevens-Johnson syndrome/toxic epidermal necrolysis in Japanese. , 2012, Drug metabolism and pharmacokinetics.

[27]  L. Naldi,et al.  Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. , 2008, The Journal of investigative dermatology.